MedTrace Logo

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

NCT04122976 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 805

Last updated 2026-05-11

No results posted yet for this study

Summary

The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his/her physician would have already made the decision to treat patient with darolutamide per local standard practice.

Conditions

Interventions

DRUG

Darolutamide(Nubeqa, BAY1841788)

The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-30
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • United States
  • Argentina
  • Austria
  • Belgium
  • Brazil
  • Canada
  • China
  • Colombia
  • Denmark
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Russia
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04122976 on ClinicalTrials.gov